<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age>83</patient-age><report-id>PHHY2012IT106893</report-id><gender>female</gender><reactions><reaction>Arthralgia</reaction><reaction>Asthenia strong</reaction><reaction>Heartburn</reaction><reaction>Epigastric pain</reaction><reaction>Edema</reaction><reaction>Azotemia 126 (unknown)</reaction><reaction>Blood urea 38 (units unknown)</reaction><reaction>Hemoglobin 8/ hemoglobin 10 (unk units)</reaction><reaction>Creatinine 2,4 (units unknown)</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>RASILEZ</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>MEDIPO</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>DIURESIX</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>CORDARONE</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>IPERTEN</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>ZYLORIC</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>LANSOX</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>CARDIOASPIRIN</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Hypertension</indication></indications><outcomes><outcome>Persistent Or Significant Disability</outcome></outcomes><country>Italy</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4149679_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125152624</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>PHHY2012IT106893</safetyreportid>
		<primarysourcecountry>IT</primarysourcecountry>
		<occurcountry>IT</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-25</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>1</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-11-19</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-21</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012IT106893</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<linkedreport>
			<linkreportnumb>182052</linkreportnumb>
		</linkedreport>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>IT</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>IT</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>CM</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19290418</patientbirthdate>
			<patientsex code="2">Female</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Glucose-6-phosphate dehydrogenase deficiency</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Arthralgia</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Arthralgia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Arthralgia</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120926</reactionstartdate>
				<reactionfirsttime>98</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Asthenia strong</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Asthenia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Asthenia</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120926</reactionstartdate>
				<reactionfirsttime>98</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Heartburn</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Heartburn</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Dyspepsia</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120926</reactionstartdate>
				<reactionfirsttime>98</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Epigastric pain</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Epigastric pain</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Abdominal pain upper</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120926</reactionstartdate>
				<reactionfirsttime>98</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Edema</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Edema</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Oedema</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120926</reactionstartdate>
				<reactionfirsttime>98</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Azotemia 126 (unknown)</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Azotemia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Azotaemia</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120926</reactionstartdate>
				<reactionfirsttime>98</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Blood urea 38 (units unknown)</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Blood urea decreased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Blood urea decreased</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20121105</reactionstartdate>
				<reactionfirsttime>138</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>41</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Hemoglobin 8/ hemoglobin 10 (unk units)</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Hemoglobin low</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Haemoglobin decreased</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120926</reactionstartdate>
				<reactionfirsttime>98</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Creatinine 2,4 (units unknown)</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Creatinine high</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Blood creatinine increased</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120926</reactionstartdate>
				<reactionfirsttime>98</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120926</testdate>
				<testname>Blood creatinine</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121105</testdate>
				<testname>Blood creatinine</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121105</testdate>
				<testname>Blood potassium</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121105</testdate>
				<testname>Blood urea</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120926</testdate>
				<testname>Haemoglobin</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121105</testdate>
				<testname>Haemoglobin</testname>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>RASILEZ</medicinalproduct>
				<obtaindrugcountry>IT</obtaindrugcountry>
				<drugauthorizationnumb>21-985</drugauthorizationnumb>
				<drugauthorizationcountry>IT</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>150</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugcumulativedosagenumb>150</drugcumulativedosagenumb>
				<drugcumulativedosageunit code="003">milligrams</drugcumulativedosageunit>
				<drugdosagetext>150 mg, daily</drugdosagetext>
				<drugdosageform normalized="coated tablet">Coated tablet</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hypertension</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-06-21</drugstartdate>
				<drugstartperiod>98</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>1</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-09-26</drugenddate>
				<drugtreatmentduration>98</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<activesubstance>
					<activesubstancename>ALISKIREN</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Abdominal pain upper</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Abdominal pain upper</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Arthralgia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Arthralgia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Asthenia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Asthenia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Azotaemia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Azotaemia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood creatinine increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood creatinine increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood urea decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood urea decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyspepsia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyspepsia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Haemoglobin decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Haemoglobin decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Oedema</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Oedema</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>MEDIPO</medicinalproduct>
				<obtaindrugcountry>IT</obtaindrugcountry>
				<drugauthorizationcountry>IT</drugauthorizationcountry>
				<drugstructuredosagenumb>20</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>20 mg, UNK</drugdosagetext>
				<drugdosageform normalized="coated tablet">Coated tablet</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-09-21</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-09-26</drugenddate>
				<drugtreatmentduration>6</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>SIMVASTATIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>DIURESIX</medicinalproduct>
				<obtaindrugcountry>IT</obtaindrugcountry>
				<drugauthorizationcountry>IT</drugauthorizationcountry>
				<drugstructuredosagenumb>10</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>10 mg, UNK</drugdosagetext>
				<drugdosageform normalized="tablet">Tablet</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-07-02</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-09-26</drugenddate>
				<drugtreatmentduration>87</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>TORASEMIDE SODIUM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>CORDARONE</medicinalproduct>
				<obtaindrugcountry>IT</obtaindrugcountry>
				<drugauthorizationcountry>IT</drugauthorizationcountry>
				<drugstructuredosagenumb>200</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>200 mg, UNK</drugdosagetext>
				<drugdosageform normalized="tablet">Tablet</drugdosageform>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-06-18</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-09-26</drugenddate>
				<drugtreatmentduration>101</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AMIODARONE HYDROCHLORIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>IPERTEN</medicinalproduct>
				<obtaindrugcountry>IT</obtaindrugcountry>
				<drugauthorizationcountry>IT</drugauthorizationcountry>
				<drugstructuredosagenumb>20</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>20 mg, UNK</drugdosagetext>
				<drugdosageform normalized="tablet">Tablet</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2003-07-02</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-09-26</drugenddate>
				<drugtreatmentduration>3375</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>MANIDIPINE HYDROCHLORIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>ZYLORIC</medicinalproduct>
				<obtaindrugcountry>IT</obtaindrugcountry>
				<drugauthorizationcountry>IT</drugauthorizationcountry>
				<drugstructuredosagenumb>150</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>150 mg</drugdosagetext>
				<drugdosageform normalized="tablet">Tablet</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2011-11-20</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-09-26</drugenddate>
				<drugtreatmentduration>312</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ALLOPURINOL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>LANSOX</medicinalproduct>
				<obtaindrugcountry>IT</obtaindrugcountry>
				<drugauthorizationcountry>IT</drugauthorizationcountry>
				<drugstructuredosagenumb>15</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>15 mg, UNK</drugdosagetext>
				<drugdosageform normalized="hard-gelatin capsule">Hard-Gelatin Capsule</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2005-09-01</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-09-26</drugenddate>
				<drugtreatmentduration>2583</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LANSOPRAZOLE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>CARDIOASPIRIN</medicinalproduct>
				<obtaindrugcountry>IT</obtaindrugcountry>
				<drugauthorizationcountry>IT</drugauthorizationcountry>
				<drugstructuredosagenumb>100</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>100 mg, UNK</drugdosagetext>
				<drugdosageform normalized="tablet">Tablet</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-03-13</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-09-26</drugenddate>
				<drugtreatmentduration>198</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ACETYLSALICYLIC ACID</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012IT106893, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report from a <Semaphore x="2009300" class="Occupation" value="Health Care Professional" score="1.00" ID="C53287">health care professional via Health </Semaphore>Authority (182052) received on 19 Nov 2012, with follow up report received from a <Semaphore x="2009300" class="Occupation" value="Health Care Professional" score="1.00" ID="C53287">health care professional via Health </Semaphore>Authority (182052) on 21 Jan 2013. This report refers to an 83-year old female patient. The patient's medical history included concurrent condition <Semaphore x="2980046" class="MedDRA LLT" value="Glucose-6-phosphate dehydrogenase deficiency" score="1.00" ID="10018444">G 6 <Semaphore x="2425341" class="Disease or Finding" value="Progressive Disease" score="1.00" ID="C35571">PD </Semaphore><Semaphore x="1988681" class="Disease or Finding" value="Glucose-6-Phosphate Dehydrogenase Deficiency" score="1.00" ID="C98933">deficiency </Semaphore></Semaphore>
    <Semaphore x="1988681" class="Disease or Finding" value="Glucose-6-Phosphate Dehydrogenase Deficiency" score="1.00" ID="C98933">(<Semaphore x="1988681" class="Disease or Finding" value="Glucose-6-Phosphate Dehydrogenase Deficiency" score="1.00" ID="C98933"><Semaphore x="627832" class="Medicine" value="Glucose" score="0.49" ID="269493">Glucose </Semaphore>6-phosphate dehydrogenase </Semaphore>deficiency</Semaphore>). Concomitant medications included Medipo (<Semaphore x="1184832" class="Medicine - Simvastatin - Dose" value="20 mg" score="0.49" ID=""><Semaphore x="1184873" class="Medicine" value="Simvastatin" score="0.49" ID="260057">simvastatin</Semaphore>) <Semaphore x="5088814691254273" class="Medicine - Simvastatin - Dose" value="20 mg" score="0.49" ID="">20 mg </Semaphore></Semaphore><Semaphore x="1789915" class="AnatomicStructure" value="Coat" score="1.00" ID="C25450">coated </Semaphore>
    <Semaphore x="1789896" class="AnatomicStructure" value="Coated Vesicle" score="1.00" ID="C32331">tablets, </Semaphore><Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally </Semaphore>from 21 Jun 2012, Diuresix (<Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303">torasemide</Semaphore>) 10 mg tablets, <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally </Semaphore>from 02 Jul 2012, Cardarone (<Semaphore x="102553" class="Medicine - Amiodarone - Dose" value="200 mg" score="0.49" ID=""><Semaphore x="102588" class="Medicine" value="Amiodarone" score="0.49" ID="280724">amiodarone</Semaphore>) <Semaphore x="440461781106689" class="Medicine - Amiodarone - Dose" value="200 mg" score="0.49" ID="">200 mg </Semaphore></Semaphore><Semaphore x="440534795550721" class="Medicine - Amiodarone - Frequency" value="tablets" score="0.49" ID="">tablets </Semaphore><Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally </Semaphore>from 18 Jun 2012, Iperten (<Semaphore x="827555" class="Medicine - manidipine - Dose" value="20 mg" score="0.49" ID=""><Semaphore x="827606" class="Medicine" value="manidipine" score="0.49" ID="243066">manidipine</Semaphore>) <Semaphore x="3554321660641281" class="Medicine - manidipine - Dose" value="20 mg" score="0.49" ID="">20 mg </Semaphore></Semaphore><Semaphore x="3554429034823681" class="Medicine - manidipine - Frequency" value="tablets" score="0.49" ID="">tablets </Semaphore><Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally </Semaphore>from 02 Jul 2003, Zyloric (<Semaphore x="77775" class="Medicine - Allopurinol - Dose" value="300 mg" score="0.49" ID=""><Semaphore x="77816" class="Medicine" value="Allopurinol" score="0.49" ID="269911">allopurinol</Semaphore>) <Semaphore x="334041081446401" class="Medicine - Allopurinol - Dose" value="300 mg" score="0.49" ID="">300 mg </Semaphore></Semaphore><Semaphore x="334126980792321" class="Medicine - Allopurinol - Frequency" value="tablets" score="0.49" ID="">tablets</Semaphore>, at a dose of 150 mg <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally </Semaphore>from 20 Oct 2011, Lansox (<Semaphore x="770572" class="Medicine - lansoprazole - Dose" value="15 mg" score="0.49" ID=""><Semaphore x="770601" class="Medicine" value="lansoprazole" score="0.49" ID="239887">lansoprazole</Semaphore>) <Semaphore x="3309581539213313" class="Medicine - lansoprazole - Dose" value="15 mg" score="0.49" ID="">15 mg </Semaphore></Semaphore><Semaphore x="3309641668755457" class="Medicine - lansoprazole - Frequency" value="hard" score="0.49" ID="">hard </Semaphore>
    <Semaphore x="2002828" class="AnatomicStructure" value="Hard Palate" score="1.00" ID="C12230">capsules </Semaphore><Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally </Semaphore>from 01 Sep 2005 and Cardioaspirin (acetyl <Semaphore x="1162573" class="Medicine - Salicylic Acid - Dose" value="100 mg" score="0.49" ID=""><Semaphore x="1162912" class="Medicine" value="Salicylic Acid" score="0.49" ID="297149">salicylic <Semaphore x="2147465" class="Procedure" value="Lysergide Measurement" score="1.00" ID="C75354">acid</Semaphore></Semaphore>) <Semaphore x="4993213014212609" class="Medicine - Salicylic Acid - Dose" value="100 mg" score="0.49" ID="">100 mg </Semaphore></Semaphore><Semaphore x="4993943158652929" class="Medicine - Salicylic Acid - Frequency" value="tablets" score="0.49" ID="">tablets</Semaphore>, <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally </Semaphore>from 13 Mar 2012, all for unknown indication and stopped on 26 Sep 2012. The patient received Rasilez (<Semaphore x="60623" class="Medicine - aliskiren - Dose" value="150 mg" score="0.49" ID=""><Semaphore x="60666" class="Medicine" value="aliskiren" score="0.49" ID="253094">aliskiren</Semaphore>) <Semaphore x="260373802385409" class="Medicine - aliskiren - Dose" value="150 mg" score="0.49" ID="">150 mg </Semaphore></Semaphore><Semaphore x="1789915" class="AnatomicStructure" value="Coat" score="1.00" ID="C25450">coated </Semaphore>
    <Semaphore x="1789896" class="AnatomicStructure" value="Coated Vesicle" score="1.00" ID="C32331">tablets daily, </Semaphore><Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally </Semaphore>for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of <Semaphore x="2038093" class="Disease or Finding" value="Hypertension" score="1.00" ID="C3117">hypertension </Semaphore>from 21 Jun 2012. On 26 Sep 2012, the patient experienced <Semaphore x="1547282" class="Disease or Finding" value="Arthralgia" score="1.00" ID="C50464">arthralgia</Semaphore>, <Semaphore x="1550618" class="Disease or Finding" value="Asthenia" score="1.00" ID="C28132">asthenia </Semaphore>strong, <Semaphore x="1874730" class="Disease or Finding" value="Edema" score="1.00" ID="C3002">edema</Semaphore>, <Semaphore x="2010375" class="Disease or Finding" value="Heartburn" score="1.00" ID="C34670">heartburn </Semaphore>and <Semaphore x="2706678" class="MedDRA LLT" value="Abdominal pain upper" score="1.00" ID="10000087">epigastric <Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303">pain</Semaphore></Semaphore>. On 26 Sep 2012, <Semaphore x="3057951" class="MedDRA LLT" value="Laboratory test" score="1.00" ID="10059938">laboratory test </Semaphore>showed <Semaphore x="2014841" class="Procedure" value="Hemoglobin Measurement" score="1.00" ID="C64848">hemoglobin </Semaphore>was 8, <Semaphore x="2769950" class="MedDRA LLT" value="Azotaemia" score="1.00" ID="10003885">azotemia </Semaphore>126, <Semaphore x="1821896" class="Procedure" value="Creatinine Measurement" score="1.00" ID="C64547">creatinine </Semaphore>2.4, <Semaphore x="2769950" class="MedDRA LLT" value="Azotaemia" score="1.00" ID="10003885">azotemia </Semaphore>126 and <Semaphore x="1848940" class="Procedure" value="Dietary Protocol" score="1.00" ID="C93051">potassium </Semaphore>6 (units and normal values not provided). On 05 Nov 2012, <Semaphore x="3057951" class="MedDRA LLT" value="Laboratory test" score="1.00" ID="10059938">laboratory test </Semaphore>showed <Semaphore x="2014841" class="Procedure" value="Hemoglobin Measurement" score="1.00" ID="C64848">hemoglobin </Semaphore>was 10, <Semaphore x="2804377" class="MedDRA LLT" value="Blood creatinine" score="1.00" ID="10005480"><Semaphore x="1608509" class="AnatomicStructure" value="Blood" score="1.00" ID="C12434">blood </Semaphore><Semaphore x="1316129" class="Medicine" value="Urea" score="0.74" ID="194669">urea </Semaphore>38, <Semaphore x="1821896" class="Procedure" value="Creatinine Measurement" score="1.00" ID="C64547">creatinine </Semaphore></Semaphore>1.5, <Semaphore x="2769950" class="MedDRA LLT" value="Azotaemia" score="1.00" ID="10003885">azotemia </Semaphore>38 and <Semaphore x="1848940" class="Procedure" value="Dietary Protocol" score="1.00" ID="C93051">potassium </Semaphore>5 (units <Semaphore x="2665498" class="AnatomicStructure" value="Unspecified Anatomic Sites" score="1.00" ID="C13411">not specified</Semaphore>). <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">Treatment </Semaphore>with Rasilez was discontinued on 26 Sep 2012. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the events <Semaphore x="1547282" class="Disease or Finding" value="Arthralgia" score="1.00" ID="C50464">arthralgia</Semaphore>, <Semaphore x="1550618" class="Disease or Finding" value="Asthenia" score="1.00" ID="C28132">asthenia </Semaphore>strong, <Semaphore x="1874730" class="Disease or Finding" value="Edema" score="1.00" ID="C3002">edema</Semaphore>, <Semaphore x="2010375" class="Disease or Finding" value="Heartburn" score="1.00" ID="C34670">heartburn </Semaphore>and <Semaphore x="2706678" class="MedDRA LLT" value="Abdominal pain upper" score="1.00" ID="10000087">epigastric <Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303">pain </Semaphore></Semaphore>was condition recovered after discontinuation of suspect <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug</Semaphore>, the seriousness was reported as <Semaphore x="2909520" class="MedDRA LLT" value="Disability" score="1.00" ID="10013050">disability </Semaphore>(serious) and causality related to <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with Rasilez. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome</Semaphore>, seriousness and causality of rest of events were not reported.Follow up report received from a <Semaphore x="2009300" class="Occupation" value="Health Care Professional" score="1.00" ID="C53287">health care professional </Semaphore>on 21 Jan 2013: Events (<Semaphore x="2014841" class="Procedure" value="Hemoglobin Measurement" score="1.00" ID="C64848">Hemoglobin </Semaphore>8/ 10, <Semaphore x="1821896" class="Procedure" value="Creatinine Measurement" score="1.00" ID="C64547">Creatinine </Semaphore>2,4, <Semaphore x="2769950" class="MedDRA LLT" value="Azotaemia" score="1.00" ID="10003885">azotemia </Semaphore>126 and <Semaphore x="1608509" class="AnatomicStructure" value="Blood" score="1.00" ID="C12434">Blood </Semaphore><Semaphore x="1316129" class="Medicine" value="Urea" score="0.74" ID="194669">urea </Semaphore>38 ) added. <Semaphore x="2091429" class="Disease or Finding" value="Laboratory Test Result" score="1.00" ID="C36292">Lab </Semaphore>data updated. Narrative updated.</narrativeincludeclinical>
				<sendercomment>Underlying age and G 6 PD defficieny could be the confounders, however available information precludes a proper causality assessment. The events are unassessable.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>